Tag - Zylö Therapeutics

Zylö’s ‘Powered by Z-pods®’ technology incorporated into BosleyMD’s new product line

Zylö’s Z-pod® topical delivery platform is being used by BosleyMD—the Thinning Hair Authority™—as a key feature in their newly launched product line, Revive+ Densifying Foam. BosleyMD is currently offering a male version and a female version through CVS and online (see link below); distribution through Walmart and Ulta Beauty is expected soon. Cable TV and online advertising will be used to promote the products. Read more >>
Read more...

Looking at the Life Sciences Industry in South Carolina

In recent years, South Carolina has become a hub of sorts for the life sciences and biotech industries. The Palmetto State has more than 1,000 companies – large and small, established and startup – that are making an impact on the local community and the world at large. Integrated Media Publishing hosted a roundtable discussion with four of the leaders in the biotech world on Jan. 4, 2024. Q. The life sciences industry has been growing. The annual economic impact...
Read more...

Zylö accepted into NYU’s exclusive Endless Frontier Labs mentorship program

Zylö Therapeutics has been selected to join the Endless Frontier Labs (EFL) 2023-2024 cohort alongside 77 other startups. Over 1,400 companies applied, including over 350 life science companies, with only 26 chosen in each of the three tracks: life sciences, deep-tech, and digital tech. Over the next nine months, EFL mentors and NYU Stern MBA students will work with Zylö’s executive team to fine-tune Zylö strategies, craft an improved pitch deck, and set/achieve value-added objectives. Read more >>
Read more...

Zylö’s ‘Powered By Z-pod’ Technology Featured in Peer-Reviewed Paper Published in Experimental Dermatology

The Z-pod® topical delivery platform was used in various in vivo studies that were highlighted in a peer-reviewed paper just published online by Experimental Dermatology titled, “Nano-encapsulated anandamide (AEA) reduces inflammatory cytokines in vitro and lesion severity in a murine model of cutaneous lupus erythematosus [CLE].” In these studies, AEA—a primary endocannabinoid that has been demonstrated to have anti-inflammatory and immunomodulatory effects—was loaded into Zylö’s proprietary Z-pod drug-delivery system. Read more >>
Read more...

Zylö Receives $294,000 NIH Phase I Grant to Advance its Cutaneous Lupus Program

Zylö Therapeutics Inc., developer of the Z-pod® topical delivery platform, has been awarded a two-year $294,000 Small Business Technology Transfer Research (STTR) grant to: (i) demonstrate that a formulation of N-acylethanolamine (AEA or anandamide) loaded into Zylö’s novel Z-pod delivery system is efficacious (and well tolerated) in a new mouse model of cutaneous lupus developed at Yale University, and (ii) conduct preliminary stability studies to prepare for an eventual investigational new drug (IND) application to the FDA. Read more >>
Read more...

SCBIO caps annual conference in Charleston with $5,000 pitch competition

To close out the SCBIO 2023 conference, three South Carolina early startups in the life sciences industry pitched venture capitalists in a “Rapid Fire: SC Super Pitch” competition in the ballroom of the Gaillard Center with hundreds of attendees in the crowd. Each company had an eight-minute pitch and then two minutes for questions and answers. Three venture capitalists — who had just spoken on a panel about how to give a good pitch — determined the winner, who was...
Read more...

VentureSouth invested $12M in 34 companies in 2022

VentureSouth, one of the Top 10 angel investment groups in North America, provided $12 million in capital investment to 34 companies in 2022, the organization announced Jan. 17. VentureSouth also made additional investments in nearly two dozen existing portfolio companies, including: Zylo Therapeutics. n November 2022, the organization announced it planned to partner with the investor group 757 Angels. The partnership, which will bring 757 Angels into VentureSouth’s network in June, is the angel investment group’s second market in Virginia...
Read more...

Zylö Receives $263,000 NIH Phase I Grant to Develop a Topical Viagra® for ED

Zylö Therapeutics Inc., developer of the Z-pod® topical delivery platform, has been awarded a one-year $263,000 Small Business Innovation Research (SBIR) grant to: (i) optimize a formulation of sildenafil (generic name of Viagra) loaded into Zylö’s proprietary silica-based Z-pods and (ii) demonstrate that the topical formulation is comparable in efficacy to orally administered sildenafil in a mouse model of erectile dysfunction [ED], with aged mice. The grant is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases,...
Read more...

Zylö Receives $600,000 NIH Phase I Grant to Develop a Novel Therapeutic to Treat Onychomycosis (Nail Fungus)

Zylö Therapeutics Inc., developer of the Z-pod® topical delivery platform, has been awarded a two-year $600,000 Small Business Innovation Research (SBIR) grant to generate a final formulation of Zylö’s proprietary nitric oxide-releasing topical drug candidate optimized for the treatment of onychomycosis. The grant is sponsored by the National Institute of Allergy and Infectious Diseases, a division of the NIH. Read more >>
Read more...

Nine Upstate organizations named as 2022 InnoVision Awards finalists

Nine Upstate organizations were named as 2022 InnoVision Awards finalists, the organization’s board of directors announced Aug. 2. The awards honor South Carolina individuals and organizations for impactful innovations under development in the state within the last 18 months. Awards will be given in six categories. One of The nominees: Technology Integration-Zylo Therapeutics Inc. – Greenville. All finalists will be recognized during the virtual InnoVision 2022 Meet the Finalists Series sponsored by South Carolina Research Authority. Read more >>
Read more...